Clinical utility of dronabinol in the treatment of weight loss associated with HIV and AIDS

Melissa E Badowski1
Sarah E Perez2

1Department of Pharmacy Practice, Section of Infectious Diseases Pharmacotherapy, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA; 2Infectious Diseases Clinic, Tufts Medical Center, Boston, MA, USA

Abstract: Since the beginning of the HIV/AIDS epidemic, weight loss has been a common complaint for patients. The use of various definitions defining HIV wasting syndrome has made it difficult to determine its actual prevalence. Despite the use of highly active antiretroviral therapy, it is estimated that the prevalence of HIV wasting syndrome is between 14% and 38%. HIV wasting syndrome may stem from conditions affecting chewing, swallowing, or gastrointestinal motility, neurologic disease affecting food intake or the perception of hunger or ability to eat, psychiatric illness, food insecurity generated from psychosocial or economic concerns, or anorexia due to medications, malabsorption, infections, or tumors. Treatment of HIV wasting syndrome may be managed with appetite stimulants (megestrol acetate or dronabinol), anabolic agents (testosterone, testosterone analogs, or recombinant human growth hormone), or, rarely, cytokine production modulators (thalidomide). The goal of this review is to provide an in-depth evaluation based on existing clinical trials on the clinical utility of dronabinol in the treatment of weight loss associated with HIV/AIDS. Although total body weight gain varies with dronabinol use (–2.0 to 3.2 kg), dronabinol is a well-tolerated option to promote appetite stimulation. Further studies are needed with standardized definitions of HIV-associated weight loss and clinical outcomes, robust sample sizes, safety and efficacy data on chronic use of dronabinol beyond 52 weeks, and associated virologic and immunologic outcomes.

Keywords: dronabinol, weight loss, HIV/AIDS, HIV wasting syndrome, cachexia

Introduction

Since the beginning of the HIV/AIDS epidemic, weight loss has been a common complaint for patients. The initial definition of HIV wasting syndrome was defined by the Centers for Disease Control and Prevention in 1987 as the involuntary weight loss of greater than 10% of baseline body weight in addition to 1) chronic weakness, 2) diarrhea (two or more loose stools per day), or 3) documented fever lasting for more than 1 month.1 Since then, updated definitions have become available to encompass rapid decreases in weight and designed to include low-weight individuals without available baseline weight that the previous definition would have excluded. In addition, the updated definition requires one of the following criteria with a diagnosis of HIV: 1) 10% unintentional weight loss over 12 months, 2) 7.5% unintentional weight loss over 6 months, or 3) unintentional weight loss of more than 5% over 3 months if other causes or factors of weight loss could not be ruled out. For individuals without documented baseline weight, those meeting the criteria for HIV wasting syndrome would include 5% body cell mass (BCM) loss within 6 months; in men: BCM <35% of total body weight (TBW) and body mass index (BMI) <27 kg/m2; in women: BCM...
<23% of TBW and BMI <27 kg/m²; or BMI <20 kg/m² regardless of BCM in men and women. The most recent proposed definition of HIV wasting syndrome (TBW loss >10% from initial visit, BMI <20 kg/m², or an unintentional TBW loss >5% in 6 months and persisting for more than 1 year) focused on the rate of weight loss as well as the reality that patients present at different stages. Although the initial definition is no longer used, recent definitions have led to varying reports of incidence and prevalence of HIV wasting syndrome.

Prior to the availability of protease inhibitors, male AIDS patients weighed less than 90% of their ideal body weight or lost greater than 10% of their TBW. Since the development of highly active antiretroviral therapies (HAART), the incidence and prevalence of HIV wasting syndrome have declined but still remain a concern in patients living with HIV/AIDS. Despite successful initiation of HAART, the prevalence of weight loss and wasting was similar to those who were antiretroviral-naïve or failing HAART. HIV wasting syndrome may stem from conditions affecting chewing, swallowing, or gastrointestinal motility, neurologic disease affecting food intake or the perception of hunger or ability to eat, psychiatric illness, food insecurity generated from psychosocial or economic concerns, or anorexia due to medications, malabsorption, infections, or tumors. The use of various definitions defining HIV wasting syndrome has made it difficult to determine its actual prevalence. Despite HAART, it is estimated that the prevalence of HIV wasting syndrome is between 14% and 38%. Higher prevalence estimates for HIV wasting syndrome may be due to updated definitions compared to strict criteria that were initially proposed, which may have underestimated the true incidence and prevalence. In a managed care population receiving HAART, it was reported that between 2005 and 2007, the prevalence of HIV wasting syndrome was 8.3% and associated with significantly higher annual health-care costs as well as significantly more ambulatory care, and more emergency room and inpatient visits ($P<0.0001$).

When all definitions of HIV wasting syndrome were included, a significant risk of death was noted for each 1% increase in weight loss from baseline weight. Furthermore, an 11% increase in the risk of death was associated with each 1% increase in weight loss from the last visit. Patients not receiving HAART, a significant relationship was found for each log10 increase in HIV viral load that correlated with a 0.92 kg decrease in body weight ($P=0.003$), yet weight change was not observed during HAART. This same study demonstrated that for every CD4 cell count decrease of 100 cells/mm³, a 0.35 kg decrease in body weight was observed ($P<0.001$). Although there are no current treatment standards for the management of HIV wasting syndrome and weight loss, initiation of HAART and viral suppression tends to promote weight gain, on average, 10%–25% annually. For patients achieving virologic suppression but still experiencing weight loss despite HAART, pharmacologic intervention may be warranted to promote weight gain.

Pathophysiology of HIV wasting syndrome

The exact mechanism of how HIV causes weight loss is not well understood, yet causes may include inadequate caloric intake and changes in metabolism. Inadequate caloric intake may arise due to depression, financial hardships, inability to chew or swallow secondary to opportunistic infections, malabsorption (due to nausea or diarrhea), and medication toxicities. Changes in metabolism have been associated with HIV wasting syndrome and may stem from changes in metabolic demands, cytokine dysregulation, and hormonal changes. In patients with untreated HIV and subsequent weight loss, the resting energy expenditure was approximately 10%–35% greater (possibly higher in patients with opportunistic infections) compared with healthy individuals. Hypogonadism may contribute to weight loss in as many as 50% of males and females living with HIV. The mechanism associated with low testosterone levels was found to be associated with decreased protein synthesis, causing a decrease in lean body mass. Finally, for HIV-positive patients experiencing acute infections, cytokine (interleukin-6, interleukin-1b, and tumor necrosis factor-α) production increased and was correlated with significant weight loss in HIV.

Treatments for HIV wasting syndrome

Various treatment options exist for HIV wasting syndrome and include appetite stimulants (megestrol acetate, dronabinol, and mirtazapine), anabolic agents (testosterone, testosterone analogs, and recombinant human growth hormone [rhGH]), and, rarely, cytokine production modulators (thalidomide). The most commonly used agents for initial management, upon virologic suppression, of HIV wasting syndrome are appetite stimulants since they promote weight gain and assist in minimizing anorexia. The decision of which agent(s) to choose should include comorbidities, drug–drug interactions, past medical history, and the ability to use and tolerate certain formulations.
Anabolic agents
Anabolic agents such as testosterone, synthetic testosterone analogs, and rhGHs differ from appetite stimulants in that these agents increase muscle mass, which may account for weight gain. Testosterone and testosterone analogs are recommended in patients with primary and hypogonadotropic hypogonadism, repletion in instances of low levels, low libido, and HIV wasting (in the presence or absence of HAART). Testosterone and testosterone analogs increased TBW as much as 3.5 kg. One benefit of testosterone and its analogs is the variety of available formulations. Testosterone levels should be monitored every 3–6 months after initiation of therapy and annually, thereafter. Although various metabolic, dermatologic, central nervous system (CNS), and endocrine adverse effects are associated with testosterone and testosterone analogs, minimal toxicities were reported in studies of HIV wasting syndrome.

rhGHs mimic natural human growth hormone in order to increase weight gain, since it minimizes the breakdown of protein and depletion of nitrogen. rhGHs should be reserved in severe cases since this requires a daily or every other day subcutaneous injection. Changes in TBW ranged between 0.7 and 3.2 kg. Similar adverse effects seen with testosterone and testosterone analogs are associated with rhGHs and include arthralgia and myalgia.

Cytokine production modulators
The cytokine production modulator, thalidomide, is rarely used due to its significant toxicities and needs to be dispensed through a special restricted distribution program. Its effects on TBW gain has been reported to be 1.5–2.2 kg and is reserved for severe and refractory cases of HIV wasting syndrome due to its severe adverse effect profile (edema, thromboembolism, grade 3/4 rash, infection, liver function test abnormalities, diarrhea, hypersensitivity, fever, and peripheral neuropathy). Thalidomide is thought to exhibit its mechanism by acting as a TNF-α inhibitor by reducing TNF-α production and promoting TBW gain.

Appetite stimulants
Megestrol acetate
Megestrol acetate is an oral suspension (40 mg/mL) or concentrated suspension (125 mg/mL) approved for the management of anorexia, cachexia, or unexplained weight loss associated with AIDS. Although the mechanism of action is unknown, megestrol acetate may enhance appetite stimulation by antagonizing the metabolic effects of catabolic cytokines. The recommended dose of megestrol acetate oral suspension is 400–800 mg/d (2–4 teaspoonfuls). Megestrol acetate ES (enhanced stability), also referred to as the concentrated suspension, has a recommended daily dose of 625 mg/day (1 teaspoonful). Megestrol acetate ES contains 0.06% ethanol and is associated with rapid dissolution and increased absorption when compared to the oral suspension (40 mg/mL). In addition, this formulation requires a smaller volume of liquid, which is beneficial for those with dysphagia or anorexia. Both suspension formulations can be stored at room temperature (between 15°C and 25°C). On average, megestrol acetate has been associated with an increase of 4–5 kg (range: 0.863–7.3 kg) in TBW over a period of 12 weeks.

Although rarely used, the protease inhibitor, indinavir, experienced a significant decrease in exposure when combined with megestrol acetate. It is recommended to increase the dose of indinavir if combination therapy with megestrol acetate is used. Megestrol acetate has also been found to reduce anticoagulant effects. Therefore, careful consideration should occur prior to initiation of megestrol acetate, because of the increased risk of procoagulant effects and thromboembolism. Megestrol acetate is contraindicated with the use of dofetilide since it may increase the serum concentration of dofetilide.

Reported adverse effects with megestrol acetate use include thromboembolism, adrenal insufficiency, and metabolic disorders. In patients receiving protease inhibitors, there may be an increased risk for overlapping toxicities such as adrenal insufficiency and hyperglycemia.

Mirtazapine
Although not approved for HIV wasting syndrome, mirtazapine is a tetracyclic antidepressant that is available as an oral tablet or an orally disintegrating tablet. Despite weight gain being reported as a common adverse effect of mirtazapine, it is for this reason that mirtazapine may be considered in HIV wasting syndrome in patients with concomitant depression. One study evaluated the use of mirtazapine in HIV-positive patients and found a 3 kg increase in TBW over a period of 12 weeks. Although the sample size was relatively small and duration of study was short, it demonstrated that mirtazapine may be another treatment option for managing weight loss in HIV patients with depression. Appetite stimulation associated with mirtazapine use is thought to be secondary to blocking serotonin 5-HT1b and 5-HT2 receptors as well as inhibiting the release of neuropeptide Y. Mirtazapine has also been associated with antiemetic effects through inhibition of 5-HT3 receptors.
It is recommended to initiate mirtazapine at 15 mg daily and titrate to effect. The daily dose of mirtazapine should not exceed 60 mg daily. Titration to therapeutic effect should occur every 1–2 weeks based on safety and tolerability.

If coadministered with efavirenz, mirtazapine may increase the likelihood of toxicities and CNS adverse effects such as drowsiness. Since mirtazapine is a substrate of CYP2D6, CYP1A2, and CYP3A4, coadministration with efavirenz may lead to inhibitory or inducing effects of mirtazapine, whereas protease inhibitors may lead to inhibitory effects of mirtazapine. In the clinical setting, these agents are frequently administered concomitantly but agents should be monitored for the increased development of adverse effects. Other agents that act as CNS depressants should be administered cautiously with mirtazapine because of its enhanced CNS depressant effects. Additional adverse effects associated with mirtazapine use may include increased serum cholesterol and triglyceride levels, constipation, xerostomia, and orthostatic hypotension.

**Dronabinol (an in-depth review)**

Dronabinol is an orally active cannabinoid that acts on the CNS. Dronabinol is a synthetic form of delta-9-tetrahydrocannabinol (THC), which is a naturally occurring component of Cannabis sativa L and activated cannabinoid receptors (CB) CB1 and CB2. Although dronabinol has a similar affinity for CB1 and CB2 receptors, efficacy is less at CB2 receptors. When CB1 is activated, marijuana-like effects occur and provide appetite enhancement, analgesia, and muscle relaxation. The same effects are not seen when CB2 activation occurs. Dronabinol acts on CB1 receptors in the CNS to produce affective, sensory, somatic, and cognitive psychological effects as well as central sympathomimetic activity manifesting as tachycardia and/or conjunctival injection. Occasional reports of orthostatic hypotension and/or syncopal episodes due to dronabinol were described, but these subsided within 12 days of treatment initiation. Dronabinol appears to have reversible effects on appetite, mood, cognition, memory, and perception and occur with higher frequency in patients on higher doses.

After administration, the onset of action is approximately 0.5–1 hour and peak effect is 2–4 hours after administration. Psychoactive effects last 4–6 hours, while the appetite stimulant effect of dronabinol may continue for 24 hours or longer after administration. Although tachyphylaxis and tolerance may develop to some pharmacologic effects of dronabinol and other cannabinoids with chronic use, they are not expected to develop to the appetite stimulant effect of dronabinol. The most common adverse effects attributed to dronabinol are dose-dependent CNS effects, including abnormal thinking, dizziness, somnolence, and paranoia. Caution should be used when operating machinery or driving with dronabinol use as it may impair physical or mental abilities. Caution should also be observed in patients with a history of substance abuse because of the potential development of tolerance and dependence with prolonged use of dronabinol, but as previously mentioned it is unlikely to occur to the appetite stimulant properties of dronabinol. For patients with a history of seizure disorder, the development of new seizure activity should prompt discontinuation of dronabinol as it has the potential to lower seizure threshold.

Dronabinol is available as 2.5, 5, and 10 mg oil-filled, oral soft gelatin capsules. Dronabinol must be stored in a cool or refrigerated environment (between 8°C and 15°C). When used for its appetite stimulant properties in the management of weight loss in HIV/AIDS, the initial dose of dronabinol is 2.5 mg by mouth twice daily before lunch and dinner. In patients unable to tolerate the initial dose, dronabinol may be reduced to 2.5 mg by mouth once daily in the evening or at bedtime. The dose of dronabinol may be titrated gradually to response and tolerability to a maximum daily dose of 10 mg by mouth twice daily. The use of dronabinol should be avoided in individuals with a history of hypersensitivity to cannabinoids or sesame oil.

Oral absorption of dronabinol is between 90% and 95%, of which 10%–20% reaches systemic circulation. Since it is highly lipid soluble, is has a rather large volume of distribution, which is approximately 10 L/kg. Dronabinol and its metabolites are estimated to be 97% protein bound. Dronabinol’s elimination phase uses a two-compartment model where the initial half-life is approximately 4 hours and the terminal half-life is 25–36 hours. Due to the large volume of distribution, dronabinol and its metabolites may be excreted at low levels for prolonged periods of time.

Although major drug interactions do not exist with dronabinol, dronabinol acts as a minor substrate for CYP2C9 and CYP3A4. Therefore, therapy with concomitant agents should be monitored for increased signs and symptoms of toxicity (CNS depressant effects, tachycardia, orthostasis) correlating with increased serum concentrations of dronabinol.

**Efficacy and safety data for dronabinol**

Various clinical evaluations have been conducted with the use of dronabinol (alone or in combination with other agents) and its effects on TBW gain. To date, 10 studies have evaluated...
the use of dronabinol for the management of HIV wasting syndrome. Most of these evaluations lack standard definitions for HIV wasting syndrome, inclusion/exclusion criteria, study design, ART, and reporting of clinical outcomes. Furthermore, many of these studies do not include current ART with respect to current practices, sample sizes robust enough to detect significant differences, as well as long-term safety and efficacy data with dronabinol. An extensive review of each study can be found in Table 1.18–27

Although safety and efficacy data have been documented, change in TBW with the use of dronabinol only ranged from −2.0 to 3.2 kg (Table 1).18–23,25,26 In studies with placebo controls, subjects generally lost weight when receiving placebo (range: −0.7 to 1.1 kg) (Table 1).19,20,23 One study evaluated the use of dronabinol and megestrol acetate alone or in combination and found a statistically significant increase in TBW for megestrol acetate 750 mg daily and megestrol acetate 750 mg daily plus dronabinol 2.5 mg twice daily (P<0.0001) but did not find any significant difference in TBW with dronabinol 2.5 mg twice daily or dronabinol 2.5 mg twice daily plus megestrol acetate 250 mg daily (Table 1).21 Inhaled marijuana, in the form of a cigarette, was evaluated alone or in combination with dronabinol but no statistically significant changes in TBW in any treatment group was found. Haney et al.24–25 evaluated the effects of dronabinol and marijuana in HIV-positive marijuana smokers and concluded that both dronabinol (4–8 times the recommended dose) and marijuana were well tolerated and produced substantial increases in food intake.

Dronabinol has been well tolerated at doses up to 20 mg/d and had mild-to-moderate CNS effects such as dizziness, euphoria, and sedation.18–20,22,24–27 One study demonstrated a clinically significant difference in the number of subjects reporting anxiety/nervousness with dronabinol 2.5 mg twice daily (n=25) compared to placebo (n=9) (P<0.001),20 while another study demonstrated a statistically significant increase in heart rate in subjects receiving ≥20 mg/day of dronabinol (20 mg, P<0.01; 30 mg, P<0.0001) (Table 1).24 It is interesting to note that this effect occurred only in subjects with a normal bioelectrical impedance analysis and measurement of body fat in relation to lean body mass.

Quality of life
Various quality-of-life measures have been improved in patients treated with dronabinol. When compared to placebo, appetite increased from baseline by 37% in those receiving dronabinol compared to only 17% with placebo (P=0.05).20 In the same study, for patients who completed at least 4 weeks of treatment and took 75% of their study medication, appetite increased from 38% compared to 8% receiving placebo (P<0.015). Improvement in mood was observed in 10% of patients on dronabinol compared to 2% decline in patients receiving placebo (P=0.06), and nausea decreased in 22% of those receiving dronabinol compared to 4% in the placebo arm (P=0.26). Patients were also evaluated for Karnofsky performance status to determine patients’ general well-being and activities of daily life. On a scale from 0 (representing death) to 100 (indicating normal activity), patients receiving dronabinol had a drop in Karnofsky scores by 2.5 points compared to no change in those receiving placebo (P=0.18).20

Another study evaluated quality of life by comparing four arms: 1) dronabinol 2.5 mg BID, 2) megestrol acetate 750 mg daily, 3) megestrol acetate 750 mg daily + dronabinol 2.5 mg BID, 4) megestrol acetate 250 mg daily + dronabinol 2.5 mg BID.21 No significant changes over time were identified nor any difference between the treatment arms in terms of Karnofsky performance status, functional assessment of HIV infection score, visual analog scale for mood, or visual analog scale for nausea. Among the entire study population, the visual analog scale (VAS) for hunger improved after the first week of therapy, with a weekly sum score for breakfast decreasing from 170 to 130 (P=0.0002), for lunch from 183 to 112 (P=0.0001), and for dinner from 192 to 114 (P=0.0001). There were no differences between groups and no significant change after the first week. For perception scores on a scale of 0 (no improvement) to 10 (improvement), improvement in social and family life increased from 6.8 at baseline to 7.8 at week 4 between all study groups (P=0.005) and improvements in additional unspecified concerns affecting quality of life from 7 at baseline to 8 after 4 weeks (P=0.003).

In a study evaluating short-term, high-dose dronabinol (10 mg four times daily) plus inhaled marijuana compared to placebo plus inhaled marijuana, dronabinol significantly increased VAS positive effect on days 1–8 and days 9–16 (P<0.01) as well as sleep efficiency on days 1–8 (P<0.01).27 No significant effect was seen on VAS anxiety, somatic symptoms, or negative effects. Although dronabinol has been associated with improved quality of mood and sleep, additional studies are needed to evaluate prolonged use of dronabinol on these parameters.

There is limited data evaluating patient satisfaction and acceptability of dronabinol use. One study compared dronabinol and marijuana use in various doses for HIV-positive marijuana smokers.28 Ratings of “good drug effect,” “mellow,” and “high” were significantly increased after taking dronabinol 10 mg compared to dronabinol 5 mg in those also
<table>
<thead>
<tr>
<th>Study</th>
<th>Definition of wasting</th>
<th>Concurrent ART</th>
<th>Duration of follow-up (weeks)</th>
<th>Treatment groups</th>
<th>Number of patients</th>
<th>Clinical outcomes</th>
<th>Adverse effects</th>
<th>Discontinuations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gorter et al</td>
<td>None</td>
<td>Zidovudine in 6 patients</td>
<td>20</td>
<td>Dronabinol 2.5 mg PO TID PRN (max: 20 mg/d)</td>
<td>10</td>
<td>0.54 kg/mo (range –1.17 to 5.79 kg/mo) (P=0.01)</td>
<td>Euphoria, sedation</td>
<td>None</td>
</tr>
<tr>
<td>Struve et al</td>
<td>≥2.25 kg TBW loss</td>
<td>Unknown</td>
<td>5</td>
<td>Dronabinol 5 mg PO BID before meals Placebo</td>
<td>12</td>
<td>0.5 (P=0.13) 3.48 kcal/kg (P=NS) – 0.7 0.84 kcal/kg</td>
<td>Mood-altering effect, sedation</td>
<td>2</td>
</tr>
<tr>
<td>Beal et al</td>
<td>≥2.3 kg TBW loss</td>
<td>Yes</td>
<td>6</td>
<td>Dronabinol 2.5 mg PO BID Placebo</td>
<td>50</td>
<td>0.1 – – –</td>
<td>10% mood improvement Nervousness (P&lt;0.001); 43% overall AE (P&lt;0.001)</td>
<td>6</td>
</tr>
<tr>
<td>Timpone et al</td>
<td>≥10% TBW loss or BMI ≤20.5 kg/m² for 18–34 years or ≥22.5 kg/m² for ≥35 years of age</td>
<td>Yes</td>
<td>12</td>
<td>Dronabinol 2.5 mg PO BID Megestrol acetate 750 mg/d Megestrol acetate 750 mg/d + dronabinol 2.5 mg PO BID Megestrol acetate 250 mg/d + dronabinol 2.5 mg PO BID</td>
<td>13 13 13</td>
<td>–2.0±1.3 6.5±1.1 6.0±1.0 (P=0.0001) –0.3±1.0</td>
<td>VAS for mood (P=NS) between arms Dronabinol related: CNS events Megestrol-related: dyspnea, liver enzyme changes, hyperglycemia</td>
<td>2 3 5</td>
</tr>
<tr>
<td>Beal et al</td>
<td>≥2.3 kg weight loss</td>
<td>Yes</td>
<td>52</td>
<td>Dronabinol 2.5 mg PO daily or 2.5 mg PO BID (max: 20 mg/d)</td>
<td>94</td>
<td>Prior dronabinol use: 0.4±3.3 to 1.3±3.8 Prior placebo: –1.2±4.4 to 0.0±4.0</td>
<td>Anxiety, confusion, depersonalization, dizziness, euphoria, somnolence, and thinking abnormality</td>
<td>19</td>
</tr>
<tr>
<td>Abrams et al</td>
<td>None</td>
<td>Yes</td>
<td>3</td>
<td>Dronabinol 2.5 mg PO TID (max: 30 mg/d) Inhaled marijuana, I complete cigarette (0%, 1.8%, 2.8%, or 3.9%) TID Placebo</td>
<td>22 20 20</td>
<td>3.2 (–1.4 to 7.6, P=0.004) 3.0 (–0.75 to 8.6, P=0.021) 1.1 (–1.4 to 5.2)</td>
<td>Unknown</td>
<td>None</td>
</tr>
<tr>
<td>Study</td>
<td>BMI/Cancer</td>
<td>Pal</td>
<td>Study Type</td>
<td>Intervention</td>
<td>Medication</td>
<td>Treatment</td>
<td>Toxicity</td>
<td>Adverse Effect</td>
</tr>
<tr>
<td>------</td>
<td>-----------</td>
<td>-----</td>
<td>------------</td>
<td>-------------</td>
<td>------------</td>
<td>-----------</td>
<td>----------</td>
<td>-------------</td>
</tr>
<tr>
<td>Haney et al.</td>
<td>&lt;90% BCM/height</td>
<td>Yes</td>
<td>4</td>
<td>Dronabinol (0, 10, 20, 30 mg PO) vs marijuana (0.0%, 1.8%, 2.8%, 3.9%) in both groups</td>
<td>Dronabinol</td>
<td>None</td>
<td>10, 20 mg well tolerated. Marijuana 1.8%, 2.8%, 3.9% THC well tolerated</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Low BIA group 15</td>
<td>Caloric consumption affected in both groups vs placebo (P&lt;0.01)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Normal BIA group 15</td>
<td>Caloric consumption unaffected by cannabinoids</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haney et al.</td>
<td>None</td>
<td>Yes</td>
<td>6</td>
<td>Dronabinol 5 mg PO QID</td>
<td>Dronabinol 10 mg PO QID</td>
<td>1.2 (P&lt;0.01)</td>
<td>Improved sleep Well tolerated None</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Inhaled marijuana 2% QID</td>
<td>Inhaled marijuana 3.9% QID</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.1 (P&lt;0.01)</td>
<td>Higher doses of marijuana and dronabinol (P&lt;0.005) and</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>De Jesus et al.</td>
<td>None</td>
<td>Yes</td>
<td>52</td>
<td>Dronabinol 9.6–12.1 mg/d</td>
<td>Placebo + inhaled marijuana</td>
<td>-0.2±0.5 (P=0.001)</td>
<td>Increased VAS positive affect and sleep efficiency Few negative subjective or cognitive effects Unknown</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Dronabinol 10 mg PO QID + inhaled marijuana</td>
<td>Placebo + inhaled marijuana</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>1.0±1.1 (P=NS)</td>
<td>3,277.1±385 calories</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** AE, adverse effect; ART, antiretroviral therapy; BCM, body cell mass; BIA, bioelectrical impedance analysis; BID, twice daily; BMI, body mass index; CNS, central nervous system; PO, per os; QID, four times a day; QOL, quality of life; TBW, total body weight; TID, thrice daily; VAS, visual analog scale.
receiving marijuana doses of 2% or 3.9% THC (P<0.005). Those taking the dronabinol 10 mg dose and 3.9% THC marijuana had increased dronabinol ratings for good effect, liking, strength, and willingness to take dronabinol again. Dronabinol 10 mg did have significant increased ratings of inability to concentrate (P<0.01). More studies are needed that evaluate acceptability and subjective effects of dronabinol use.

**Conclusion**

Although the incidence of HIV wasting has decreased since the introduction of HAART, those who continue to be affected by HIV wasting syndrome require treatment to limit associated morbidity and mortality. In individuals with HIV/AIDS who have decreased appetite and weight loss unattributed to other comorbidities, such as androgen deficiency or depression, dronabinol is a well-tolerated option to promote appetite stimulation. Although TBW gain varies with dronabinol use (~2.0 to 3.2 kg), a benefit of dronabinol use allows for standardized THC levels and is not associated with a rapid high unlike smoked or inhaled marijuana. Many of the adverse effects seen with dronabinol are dose dependent. Dosing of patients should be individualized based on appetite stimulation and tolerability. Limitations for dronabinol use include individuals unable to take an oral capsule, unable to maintain dronabinol in a cool or refrigerated environment, or those with hypersensitivity to any components of dronabinol (including sesame oil). Further studies are needed with standardized definitions of HIV-associated weight loss and clinical outcomes, robust sample sizes, safety and efficacy data on chronic use of dronabinol beyond 52 weeks, and associated virologic and immunologic outcomes.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


